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ABSTRACT
Background Aneurysm wall degeneration is linked 
to growth and rupture. To address the effect of aspirin 
(ASA) on aneurysm formation under various wall 
conditions, this issue was analyzed in a novel rabbit 
bifurcation model.
Methods Bifurcation aneurysms created in 45 New 
Zealand White rabbits were randomized to vital (n=15), 
decellularized (n=13), or elastase- degraded (n=17) wall 
groups; each group was assigned to a study arm with or 
without ASA. At follow- up 28 days later, aneurysms were 
evaluated for patency, growth, and wall inflammation at 
macroscopic and histological levels.
Results 36 rabbits survived to follow- up at the end of 
the trial. None of the aneurysms had ruptured. Patency 
was visualized in all aneurysms by intraoperative 
fluorescence angiography and confirmed in 33 (92%) 
of 36 aneurysms by MRI/MRA. Aneurysm size was 
significantly increased in the vital (without ASA) and 
elastase- degraded (with and without ASA) groups. 
Aneurysm thrombosis was considered complete in three 
(50%) of six decellularized aneurysms without ASA by 
MRI/MRA. Locoregional inflammation of the aneurysm 
complex was significantly reduced in histological analysis 
among all groups treated with ASA.
Conclusion ASA intake prevented inflammation of both 
the periadventitial tissue and aneurysm wall, irrespective 
of initial wall condition. Although ASA prevented 
significant growth in aneurysms with vital walls, this 
preventive effect did not have an important role in 
elastase- degraded pouches. In possible translation to the 
clinical situation, ASA might exert a potential preventive 
effect during early phases of aneurysm formation in 
patients with healthy vessels but not in those with highly 
degenerative aneurysm walls.
INTRODUCTION
Aneurysmal subarachnoid hemorrhage due to 
rupture of an intracranial aneurysm remains one of 
the most devastating neurological diseases with a 
high associated mortality and morbidity.1 2 Chronic 
inflammatory processes of the vessel wall are known 
to have an important role in intracranial aneurysm 
wall pathobiology that leads to further growth 
and rupture.3 4 In this context, the role of aspirin 
(ASA) as a potential protectant against intracranial 
aneurysm rupture by antagonizing the inflammatory 
microenvironment has been elucidated in previous 
animal studies, human case–control studies, and 
histological analyses of human aneurysm domes 
sampled from unruptured and ruptured intracranial 
aneurysms.3 5–8
For instance, continuous ASA intake for 12 
weeks was shown to reduce macrophage- mediated 
aneurysm wall signal intensity in MRI of human 
unruptured intracranial aneurysms.9 Additionally, 
compared with unruptured aneurysms, upregu-
lation of prostaglandin E2 synthase-1 (PGES-1) 
and cyclooxygenase-2 (COX-2) was observed in 
ruptured specimens.5 Compared with the control 
group, regular ASA intake 3 months before micro-
surgical clipping decreased vessel wall signal 
intensity on MRI, lowered PGES-1 and COX-2 
concentrations, and decreased levels of macro-
phages in aneurysm tissues.10 In a study of patients 
taking ASA for 6 months or more, similar vessel wall 
results were noted using high- resolution 3 Tesla (T) 
MRI.11 A 10- year retrospective review of patients 
with multiple intracranial aneurysms showed that 
ASA significantly decreased the aneurysm growth 
rate over time.12
Nonetheless, information is lacking about the 
effect of ASA intake on the natural course of bifur-
cation aneurysms with vital and already degraded 
wall conditions. Therefore, in this experimental 
bifurcation aneurysm rabbit model, we specifically 
analyzed inflammation and aneurysm growth over 
time in groups with varied wall characteristics.
MATERIALS AND METHODS
Study design
To analyze the effects of ASA on aneurysm forma-
tion under various wall conditions in a rabbit 
model, bifurcation aneurysms were created in 45 
New Zealand White rabbits (figure 1). Animals 
were randomly allocated to one of three groups 
as vital (n=15), decellularized (n=13), or elastase- 
degraded (n=17) using a web- based randomization 
system ( www. sealedenvelope. com). Each group was 
then assigned to a study arm with or without ASA 
(n=6).
Primary outcomes were defined as aneurysm 
patency and aneurysm growth 28 days after its 
copyright.
 on A













2 Wanderer S, et al. J NeuroIntervent Surg 2021;0:1–7. doi:10.1136/neurintsurg-2020-017261
Basic science
creation based on MRI findings. Secondary outcomes were 
aneurysm inflammation and thrombus organization. Patency of 
the aneurysm and its parent artery complex was controlled by 
fluorescence angiography at intraoperative creation and assessed 
at follow- up after terminal MRI.13 The study design is shown in 
figure 1.
Experiments were approved by the Local Committee for 
Animal Care of the Canton Bern, Switzerland (BE 108/16). The 
45 female rabbits with a mean weight of 3722.64 g (±276.34 g) 
and mean age of 16 weeks (±3 days) were housed at room 
temperature of 22–24°C with a 12- hour light/dark cycle. The 
rabbits had free access to a pellet and hay diet as well as water. 
All animals received daily care in accordance with the local 
institutional guidelines. Animals allocated to the ASA groups 
exclusively had access to ASA water. Therefore, correct intake 
of ASA was calculated by monitoring drinking water twice daily. 
Surgeries were conducted in the Experimental Surgery Facility 
of the same department under supervision of a board- certified 
veterinary anesthesiologist. The ARRIVE guidelines were strictly 
followed.14
Bifurcation aneurysm model and surgical technique
Intraoperative surgical characteristics were recorded (see online 
supplemental figure 1). Detailed techniques of graft harvesting, 
graft preparation, and microsurgical creation of the arterial 
bifurcation have been described elsewhere.15 Briefly, bifurcation 
aneurysms were created by end- to- side anastomosis of the right 
common carotid artery (CCA) to the left CCA, and interposition 
of an arterial pouch in 36 female New Zealand White rabbits 
(see online supplemental figure 2 and online supplemental video 
1).
Arterial wall degradation protocols
Considering the protocol without prior treatment, the autolo-
gous graft was harvested and directly transplanted to the same 
animal (autograft). Treatment followed either the sodium dodecyl 
sulfate (SDS) or the elastase protocol. For the SDS adminis-
tration, tissue was decellularized according to a previously 
published protocol.4 For elastase administration, graft decellu-
larization followed the details of a previously published protocol 
as well (detailed protocol in Supplementary Materials).15
Figure 1 . Flowchart of the study design and follow- up modalities. Of 59 total animals, 36 were included for final analysis and 23 were excluded 
(ie, 14 in pilot study and 9 early dropouts (2 with complete thrombosis of the left parent artery; 3 with neurologic worsening; 1 with intraoperative 
digestion of the left carotid artery with subsequent euthanasia; 3 deaths of unknown causes) (Panel A). Patency of the aneurysm complex was 
confirmed via fluorescence angiography at day 0 intraoperatively, and with magnetic resonance angiography and fluorescence angiography 28 days 
after surgery (Panel B).
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Magnetic resonance imaging
Before final MRI, all animals were weighed and received a subcu-
taneous application of 0.1 mg/kg acepromazine (Prequillan, 
10 mg/mL, Fatro, Italy) and buprenorphine (Temgesic, 0.3 mg/
mL, Indivior AG, Switzerland) (0.03 mg/kg). Scanning time 
performed via 3 T Magnetom Skyra (Siemens, Munich, 
Germany) (see detailed protocol in Supplementary Materials) 
was 45 min per animal. On completion of fluorescence video 
angiography, the animals were euthanized by intravenous injec-
tion of 150–300 mg/kg pentobarbital (Esconarkon, 300 mg/mL, 
Streuli Pharma, Switzerland).
Measurement of the pre- and post-mortem aneurysm 
volumes
Aneurysms were measured and photographically documented 
before implantation. Aneurysm volume was calculated based 
on the formula: π × height × width/2 × length/2. At final 
MRI, aneurysm volumes were quantified by 3D reconstruction 
(VitreaCore, Canon, Tokia, Japan); partial thrombogenesis was 
detected by this imaging and macroscopic evaluation (see online 
supplemental figure 3). Post- mortem macroscopical analysis 
and documentation of the aneurysm volume was carried out to 
assure a certain comparability.
Histology
For histological processing, paraffin- embedded aneurysms were 
cut in the axis of the underlying parent artery in 2 μm slices 
and stained, including hematoxylin- eosin (HE), smooth muscle 
actin (SMA), Masson- Goldner trichrome (MASA), and von Will-
ebrand factor (F8). The slides were then digitized (Omnyx VL 
120, GE, USA) and evaluated with a JVS viewer (JVS view 1.2 
full version, http:// jvsmicroscope. uta. fi/ software/, Finland). The 
light microscopy findings were analyzed qualitatively by two 
observers (SW and SS) and rated with a previously used four- tier 
grading system.4 However, our study design precluded blinding 
of the three groups and the effect of ASA. Periadventitial inflam-
mation, aneurysm wall inflammation, and neutrophils in the 
thrombus were evaluated in HE- stained slices, and periadven-
titial fibrosis was evaluated in MASA- stained slices. The pres-
ence of hematoma, cellularity, and dissection of the aneurysm 
wall and luminal thrombus were analyzed in HE- stained slices, 
whereas endothelium and neointima formation were evaluated 
in MASA- stained slices. Finally, aneurysm wall cellularity was 
assessed in SMA- stained slices and endothelium in F8- stained 
slices.
Statistical analyses
All statistical analyses were calculated using the non- parametric 
Wilcoxon–Mann–Whitney U test and/or parametric unifactorial 
variance analysis. A p value of <0.05 and <0.01 was consid-
ered significant. Data were analyzed by IBM SPSS Version 22 
(USA). The sample size per group was determined using an a 
priori sample size calculation ( BiAS. for. Windows Version 11, 
Germany). To achieve α=0.05 at β=0.2 with a sigma of 0.2, the 
sample size calculation showed that 4–8 animals per group were 
appropriate to achieve a delta between 0.3 and 0.5. Figures were 
visualized by Graph Pad Prism 8, Version 8.2.0.435 (GraphPad 
software, USA). All values are expressed as mean±SD or median 
(IQR).
RESULTS
Aneurysms in the vital group without ASA as well as in the elas-
tase groups without and with ASA showed significant growth 
patterns over 28 days (figure 2). This effect was not observed 
in the vital group with ASA, nor in the decellularized groups 
without and with ASA.
Follow-up macroscopic measurements
Aneurysm size increased in all study groups from creation 
to follow- up (see online supplemental table 1). Specifi-
cally, aneurysm size increased in the vital group without ASA 
from 6.48±4.43 mm3 at creation to 19.85±15.69 mm3 at 
follow- up (p<0.05) and with ASA from 10.01±2.13 mm3 at 
creation to 13.91±6.38 mm3 at follow- up (p=0.149). Aneu-
rysm size increased in the elastase group without ASA from 
8.03±2.64 mm3 at creation to 20.95±14.31 mm3 at 28- day 
follow- up (p<0.05) and with ASA from 9.91±4.48 mm3 at 
creation to 19.46±8.99 mm3 at follow- up (p<0.05). Aneu-
rysm size increased, although not significantly, in the decellu-
larized group without ASA from 9.88±5.79 mm3 at creation to 
14.43±9.02 mm3 at follow- up (p=0.261) and with ASA from 
13.61±2.56 mm3 at creation to 17.96±8.61 mm3 at follow- up 
(p=0.41) (see online supplemental table 1).
After 28 days, 100% patency was observed in the vital and elas-
tase groups with or without ASA and in the decellularized group 
with ASA. Complete thrombosis of the aneurysm and the parent 
artery was observed in three (50%) of six animals in the decellu-
larized group without ASA. Partial thrombosis was observed in 
three of six aneurysms in the decellularized group without ASA, 
in one (16%) of six aneurysms in both the vital group with ASA 
and the elastase group without ASA, and in all six aneurysms in 
the decellularized group with ASA. Complete and partial throm-
bosis of the aneurysm was visualized by contrast- enhanced MRI 
followed by fluorescence angiography.
Follow-up histological findings
Histological grading included periadventitial inflammation, 
aneurysm wall inflammation, neutrophils in the thrombus, and 
periadventitial fibrosis (figure 3).
ASA significantly reduced periadventitial inflammation in the 
vital, decellularized, and elastase groups (p<0.01) (figures 3 
and 4). Likewise, ASA also significantly reduced aneurysm wall 
inflammation in the vital (p<0.01), decellularized (p<0.05), 
and elastase (p<0.01) groups (figures 3 and 4). However, ASA 
did not significantly reduce neutrophils in the thrombus in the 
vital, decellularized, or elastase groups. Invasion of neutrophils 
Figure 2 . Bar graph comparing aneurysm volume (cc) at baseline 
(BL) and follow- up (FU). Vital aneurysms without ASA treatment showed 
significant patterns of growth whereas those with ASA treatment did 
not grow. All aneurysms with SDS- degenerated walls (with and without 
ASA treatment) did not grow. By contrast, all aneurysms that were 
degraded with elastase (without and with ASA treatment) showed 
significant growth during follow- up. All values are given as cubic 
centimeters (cc) and presented as median and interquartile range. * p < 
0.05 vs. corresponding group.
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was pronounced in the decellularized group compared with the 
vital and elastase groups (figure 3). Periadventitial fibrosis was 
significantly reduced in the vital (p<0.01) and elastase groups 
(p<0.05) and was more pronounced in the vital group (figure 3).
Among grading for other histological characteristics (online 
supplemental figure 4), we noted that, in all six groups, neither 
hematoma nor dissection affected the aneurysm wall, endothe-
lial cellularity was not significantly altered, and no significant 
differences developed in neointima formation. Luminal throm-
bosis was more pronounced in both decellularized groups. In 
the vital and elastase groups, neointima formation could not be 
Figure 3 . Bar graph depicting histological grading for periadventitial 
inflammation, aneurysm wall inflammation, neutrophils in the 
thrombus and periadventitial fibrosis. Analyses are grouped for vital, 
decellularized, and elastase- treated aneurysms without and with 
ASA treatment using a previously described 4- point grading system 
(0 = none, 1 = mild, 2 = moderate, 3 = severe). * p < 0.05, ** p < 
0.01 vs. corresponding group. (A) Periadventitial inflammation. ASA 
intake significantly reduced periadventitial inflammation in the vital, 
decellularized, and elastase groups. (B) Aneurysm wall inflammation. 
ASA intake significantly reduced aneurysm wall inflammation in 
the vital, decellularized, and elastase groups. (C) Neutrophils in the 
thrombus. ASA intake did not significantly reduce neutrophils in the 
thrombus in the vital, decellularized, or elastase groups. However, 
a pronounced thrombus invasion of neutrophils was observed in 
the decellularized group compared with vital and elastase groups. 
(D) Periadventitial fibrosis. ASA intake significantly reduced 
periadventitial fibrosis in the vital and elastase groups but not in the 
decellularized group.
Figure 4 . Representative microphotographs of vital, decellularized, 
and elastase- treated aneurysms without and with ASA treatment. 
Hematoxylin- eosin (HE) staining of the media (#). Scale bar: 300 mm.
(A) Vital aneurysm without ASA treatment. Aneurysm lumen (§), 
infiltration of granulocytes (Black arrows).
(B) Vital aneurysm with ASA treatment shows no sign of wall 
inflammation or periadventitial inflammation. Aneurysm lumen 
(§).
(C) Decellularized aneurysm without ASA treatment. Note the 
apical thrombus formation ($), and intense inflammation of 
aneurysm wall and periadventitia characterized by accumulating 
granulocytes (b lack arrows). Periadventitial tissue layer (black 
arrowheads).
(D) Decellularized aneurysm with ASA pretreatment shows no 
signs of inflammation of aneurysm wall (#) or periadventitia. 
Note luminal thrombus formation and sparse neutrophils in 
the outer luminal layer of the thrombus (black arrows) and 
intraluminally (black arrowheads). Aneurysm lumen (§).
(E) Elastase- treated aneurysm without ASA. Beginning luminal 
thrombus formation ($) with excessive infiltration of neutrophil 
granulocytes in the aneurysm wall (black arrows and highly 
degenerated extracellular matrix). Note excessive periadventitial 
inflammation (black arrow heads).
(F) Elastase- treated aneurysm with ASA. Note the highly 
degenerated matrix in the aneurysm wall. Note absence of 
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detected compared with the decellularized groups in which a 
stronger tendency to neointima formation was noted with ASA 
(see online supplemental figures 5-7 for illustrative histological 
samples).
General data and surgical characteristics
Of a total of 45 animals used in the experiments, 14 (4 vital, 1 
decellularized, 9 elastase) were used in a pilot study to establish 
reliable and consistent reproducible procedures. Of 36 animals 
included in the final study, no deaths occurred intraoperatively 
and no ischemic brain lesions were detected by MRI in any 
rabbit before euthanasia.
Among nine (20%) animals that died prematurely and were 
excluded from analysis, two had complete thrombosis of the left 
parent artery on postoperative days 3 and 7; three had neuro-
logic worsening and were euthanized postoperatively on days 
4, 5, and 8; one had intraoperative digestion of the left carotid 
artery and was subsequently euthanized; and three died in their 
cages of unknown causes postoperatively on days 2, 7, and 11.
Intraoperatively, 10 (23%) of 44 aneurysms showed no 
contrast enhancement in the arterial pouch on fluorescence 
angiography. These 10 aneurysms then underwent reclamping, 
reopening, and flushing with heparinized saline followed by 
thrombus evacuation. Repeat fluorescence video angiography 
confirmed patency in all 44 aneurysm cases. Physiological values 
and amplitude of blood pressure were measured in the auricular 
artery after reopening all vascular clamps.
Follow-up MRI patency rate
After 28 days, 33 (92%) of 36 of aneurysms remained open, two 
(6%) had complete thrombosis of the aneurysm and its parent 
vessel complex, and one had complete aneurysm thrombosis. 
Partial aneurysm thrombosis was observed in 11 (31%) aneu-
rysms, especially among nine (25%) in the decellularized group 
(online supplemental table 1).
DISCUSSION
This experimental study studied the effects of ASA on bifurca-
tion aneurysms in a rabbit model, specifically the natural course 
of inflammation and aneurysm growth in groups defined by wall 
characteristics as vital, decellularized, or elastase degraded. Our 
results of continuous ASA intake found significantly decreased 
aneurysm growth in vital aneurysms, mimicking early aneurysmal 
disease, as well as decreased inflammation in the periadventitia 
and aneurysm wall irrespective of any of the three initial wall 
conditions. Interestingly, ASA intake did not attenuate aneurysm 
growth in elastase- pretreated pouches. The protective effect of 
ASA in the early stage of aneurysm might be lost in progressive 
aneurysmal disease.
Vital aneurysms
To analyze potential effects of ASA in the early phase of aneu-
rysm formation, vital arterial pouches were implanted in an 
artificial arterial bifurcation. Compared with the control group, 
ASA significantly prevented aneurysm growth and, in histolog-
ical studies, significantly reduced aneurysm wall inflammation, 
periadventitial inflammation, and fibrosis.
The potential role of ASA in preventing intracranial aneurysm 
growth and rupture is multifold.6 First, it acts to block COX-2, 
which is associated with intracranial aneurysm formation and 
rupture. Hasan et al showed upregulation of PGES-1 and 
COX-2 in histological specimens of human ruptured intracranial 
aneurysms compared with unruptured intracranial aneurysms.5 
In tissue samples of patients who underwent intracranial aneu-
rysm clipping, attenuated expressions of PGES-1, COX-2, and 
macrophages were detected in the wall after 3 months of ASA 
therapy compared with the control group without ASA. As 
shown by novel imaging protocols, aneurysm wall inflammation 
was reduced in patients who received continuous ASA treatment 
prior to elective clipping.10 With regard to these issues, a vessel 
wall oriented therapy with ASA might provide an interesting 
future approach in identifying patients at high risk for intracra-
nial aneurysm rupture and/or assessing treatment response.
Decellularized aneurysms
Decellularized aneurysms did not show significant enlargement 
with or without ASA treatment. Compared with the control 
group, inflammation in the aneurysm wall and periadventitia 
was significantly reduced in the ASA arm. The role and impor-
tance of degenerated aneurysm walls in growth and rupture is 
undisputed.4 16 In general, fewer mural cells implicate a worse 
biologic response in aneurysm healing because of the inability of 
intraluminal thrombus to organize. Previously, loss of mural cells 
was shown to have an important role in furthering its progres-
sion in a saccular rat sidewall model with untreated aneurysms,4 
after coil embolization,17 and also after stent treatment.18 With 
decreased numbers, there are fewer cells that can migrate into 
the thrombus and form a neointima. Furthermore, in a side-
wall rabbit model, all aneurysms thrombosed spontaneously.19 
In our bifurcation series, in the ASA arm all aneurysms had 
partial thrombosis whereas the group without ASA had complete 
thrombosis in half of the aneurysms and partial thrombosis in 
the other half. Graft decellularization by SDS, including endo-
thelial cells, may have contributed substantially to this high rate 
of thrombosis. Therefore, other degradative compounds such as 
elastase pretreatment were further analyzed for a potential ASA 
effect on aneurysm formation in advanced disease.
Elastase-degraded aneurysms
Compared with vital aneurysms, a protective effect in preven-
tion of aneurysm growth was not observed in elastase- degraded 
pouches and ASA intake clearly failed to prevent aneurysm 
growth. After 28 days, significant growth was observed both 
with and without ASA. Therefore, while ASA intake might be 
protective during early stages of aneurysm formation with rela-
tively healthy vessel walls, this protective effect is likely to be 
lost in advanced disease. Nevertheless, aneurysm wall inflam-
mation, periadventitial inflammation, and fibrosis were signifi-
cantly reduced in the ASA group. This fact suggests that, along 
with inflammatory components, other factors driving aneurysm 
enlargement (eg, hemodynamics of a true vessel bifurcation) 
must also be considered.
In our pilot study using 14 animals, the group of nine elastase- 
treated animals was the largest; this group also included 5/9 
animals that died prematurely and contributed to the overall 
15.3% mortality rate. The reasons for the increased mortality, 
even when performing topical elastase incubation in our model, 
might be the non- specific effects of elastase in circumferential 
digestion of all tissues (shown in online supplemental figure 2C), 
leading to possible thrombogenic reactions at a molecular level.20
Use of ASA in aneurysm treatment and further clinical 
implications
Several studies have previously shown substantial increases in 
aneurysm size in deteriorated aneurysm walls in rabbits over 
time when using adjuncts such as Eastman 910 or elastase after 
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in vitro collagenase I infusion.21 In our bifurcation series, these 
observations were confirmed in both vital and elastase- degraded 
pouches. The significant aneurysm growth over time observed in 
the vital group without ASA treatment was similar to the natural 
course of bifurcation aneurysms observed in humans.2 Here, the 
significant upregulation of neutrophils in the periadventitia and 
aneurysm wall might be the cause. Accordingly, with its anti- 
inflammatory effects, ASA pretreatment in the vital group thus 
prevented significant aneurysm growth after 28 days. Aligned 
with the results of other studies, we consider that, through antag-
onizing inflammatory processes such as COX-2 and PGES-1 
inhibition, a certain degree of aneurysm wall stabilization might 
be achieved.
In a retrospective review of 146 patients, Zanaty et al observed 
that ASA intake significantly decreased the rate of intracranial 
aneurysm growth over time.12 In a large retrospective single- 
center study of 4701 patients, Can et al found that ASA intake 
was associated with a decreased risk of intracranial aneurysm 
rupture.22 Furthermore, Hudson et al clearly demonstrated that 
ASA intake beneficially modulated the inflammatory microenvi-
ronment within the intracranial aneurysm vessel wall, thereby 
preventing rupture and aneurysm growth in patients with 
multiple intracranial aneurysms over time.8 These findings were 
confirmed in other preclinical and clinical investigations.23 24
Comparable with our results, preclinical and clinical studies 
have reported similar encouraging results when targeting inflam-
matory processes in the aneurysm wall, especially with ASA, to 
avoid further growth and rupture; they also hypothesized that 
its anti- inflammatory effect might be protective in providing 
aneurysm stability.3 10 More recently, these data were further 
confirmed in population- based studies of more than 200 000 
patients with intracranial aneurysms who received low- dose 
long- term ASA therapy. Regarding the entire study population, 
the incidence of subarachnoid hemorrhage by aneurysm rupture 
was reduced by more than 20%.25 Nonetheless, the benefit of this 
conservative treatment approach must be confirmed in prospec-
tive randomized multicenter trials such as the PROTECT- U trial, 
which considered the influences of blood pressure reduction in 
combination with ASA.1
Study limitations
To the best of our knowledge, this study is the first report of 
a true bifurcation aneurysm model using arterial grafts that 
allow for a direct comparison of different wall characteristics 
(vital, decellularized, elastase degraded). Strengths of this model 
included its relatively large sample size and a multimodal data 
analysis approach (ie, baseline and follow- up fluorescence angi-
ography, MRI, histological assessment) that provided consistent 
and reliable values for results and interpretation.
The aim of these experiments was to study a biological 
concept of vessel wall biology, therefore the results of this extra-
cranial aneurysm model should be extrapolated with caution to a 
true intracranial aneurysm model. Compared with endovascular 
approaches for aneurysm induction, surgical dissection causes 
locoregional inflammation so a surgically- created aneurysm 
likely causes stronger long- lasting inflammation. To reduce this 
bias in analyzing the data as far as possible, the final follow- up 
timepoint was 28 days after surgical creation of the aneurysm. 
Furthermore, postoperative administration of meloxicam for 
analgesia may have influenced locoregional inflammation in a 
beneficial fashion. However, this bias was minimized because all 
the animals received meloxicam for only 3 days. Regarding the 
20% mortality and initial 23% rate of intraoperative thromboses 
verified by fluorescence angiography, other factors to consider 
include potential thrombogenic properties of the suture material 
and modified arterial pouches, and the learning curve required 
for this sophisticated surgical technique. Of note, initial MRI 
directly after implanting the arterial pouch would provide the 
most precise aneurysm volume, but partial thrombosis of the 
arterial pouch within 28 days detected by terminal MRI might 
potentially not depict true aneurysm growth over time and could 
even interfere in the comparison between immediate postopera-
tive MRI and MRI performed at terminal follow- up. Lastly, imme-
diate postoperative MRI was not performable because of missing 
availability, so exact macroscopic measurement was performed 
every time prior to implantation and also after terminal MRI and 
explantation of the aneurysm complex to detect macroscopic 
pattern of growth. Therefore, a certain reproducibility should be 
given but, nevertheless, macroscopic measurement after pouch 
implantation intraoperatively as well as postoperatively after 28 
days would eventually be more precise.
Besides the use of neutrophils to monitor the indirect effects 
of ASA on the inflammatory microenvironment, many specific 
parameters (eg, COX-1, COX-2) can now be measured to iden-
tify direct effects. Nevertheless, previous studies have identified 
neutrophils as the driving factors for aneurysm growth. Poten-
tial molecular targets of ASA in cerebral aneurysm pathophysi-
ology are manifold. For example, prostaglandin E2 targeted by 
ASA increases vascular permeability and attracts/activates both 
macrophages and neutrophils. Therefore, an indirect effect of 
ASA intake should be at least depicted.
Finally, although we aimed for maximal standardization, we 
cannot exclude the possibility that slight differences in aneurysm 
volumes might have been hemodynamically relevant by causing 
different shear stress.
CONCLUSIONS
We believe this to be the first report of a true bifurcation 
aneurysm model using arterial grafts that allowed for a direct 
comparison of different wall characteristics (vital, decellularized, 
elastase- degraded). Continuous ASA administration reduced 
inflammation of the aneurysm wall irrespective of the initial 
wall condition in a rabbit true bifurcation aneurysm model. ASA 
significantly prevented aneurysm growth in aneurysms with vital 
walls, whereas this preventive effect did not seem to play an 
important role in elastase- degraded pouches. Considering these 
findings, the potential preventive effect of ASA in the early phase 
of aneurysm formation in patients with healthy vessels may be 
lost in those with highly degenerative aneurysm walls.
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